tetano
Editor, Senior Moderator
Br J Haematol. 2020 Apr 18. doi: 10.1111/bjh.16727. [Epub ahead of print]
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.
Kollias A[SUP]1[/SUP], Kyriakoulis KG[SUP]1[/SUP], Dimakakos E[SUP]1[/SUP], Poulakou G[SUP]1[/SUP], Stergiou GS[SUP]1[/SUP], Syrigos K[SUP]1[/SUP].
Author information
Abstract
Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.
This article is protected by copyright. All rights reserved.
KEYWORDS:
SARS-CoV-2; anticoagulant; prophylaxis; thromboembolism; thrombosis
PMID:32304577DOI:10.1111/bjh.16727
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.
Kollias A[SUP]1[/SUP], Kyriakoulis KG[SUP]1[/SUP], Dimakakos E[SUP]1[/SUP], Poulakou G[SUP]1[/SUP], Stergiou GS[SUP]1[/SUP], Syrigos K[SUP]1[/SUP].
Author information
Abstract
Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.
This article is protected by copyright. All rights reserved.
KEYWORDS:
SARS-CoV-2; anticoagulant; prophylaxis; thromboembolism; thrombosis
PMID:32304577DOI:10.1111/bjh.16727